Table 1.
Baseline Characteristics of Study Participants, Exposed Set
| Characteristic | 30 RSVPreF3 (n = 124) |
60 RSVPreF3 (n = 126) |
120 RSVPreF3 (n = 126) |
Placebo (n = 126) |
|---|---|---|---|---|
| Age in years at first vaccination, mean (SD) | 32.5 (7.4) | 32.1 (7.9) | 31.5 (7.6) | 32.2 (7.1) |
| Age group, n (%) | ||||
| 18–32, y | 62 (50) | 64 (50.8) | 64 (50.8) | 66 (52.4) |
| 33–45, y | 62 (50) | 62 (49.2) | 62 (49.2) | 60 (47.6) |
| Country, n (%) | ||||
| Finland | 15 (12.1) | 15 (11.9) | 16 (12.7) | 15 (11.9) |
| Germany | 52 (41.9) | 54 (42.9) | 52 (41.3) | 53 (42.1) |
| United States | 57 (46.0) | 57 (45.2) | 58 (46.0) | 58 (46.0) |
| Ethnicity, n (%) | ||||
| Hispanic or Latino | 5 (4.0) | 2 (1.6) | 2 (1.6) | 2 (1.6) |
| Not Hispanic or Latino | 119 (96.0) | 124 (98.4) | 124 (98.4) | 124 (98.4) |
| Race, n (%) | ||||
| Asian | 1 (0.8) | 1 (0.8) | 2 (1.6) | 5 (4.0) |
| Black or African American | 5 (4.0) | 5 (4.0) | 4 (3.2) | 7 (5.6) |
| White | 115 (92.7) | 120 (95.2) | 117 (92.9) | 114 (90.5) |
| Other | 3 (2.4) | 0 (0) | 3 (2.4) | 0 (0) |
Abbreviations: 30 RSVPreF3/60 RSVPreF3/120 RSVPreF3, group receiving 1 dose of RSV vaccine containing 30, 60, or 120 µg of RSVPreF3 antigen; n, number of women; placebo, group receiving 1 dose of placebo; RSV, respiratory syncytial virus.